billS1838Event Thursday, August 6, 2026Analyzed

DeOndra Dixon INCLUDE Project Act of 2026

Neutral

Summary

The DeOndra Dixon INCLUDE Project Act of 2026 authorizes a Down syndrome research program at NIH but does not appropriate specific funds. It passed the Senate by voice vote on August 6, 2026, and now awaits House action. The bill has no direct near-term market impact due to its authorization-only nature and lack of specified funding.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.The bill authorizes a Down syndrome research program at NIH but does not appropriate funds.
  • 2.Passed Senate by voice vote; House action is the next step.
  • 3.No direct near-term impact on publicly traded companies due to lack of funding and specificity.

Market Implications

The bill has no material market implications. It does not create revenue streams for any publicly traded company. Investors should not expect any stock movement based on this legislation.

Full Analysis

The bill, S.1838, passed the Senate on August 6, 2026, by voice vote with an amendment in the nature of a substitute. It is now awaiting action in the House. The legislation amends the Public Health Service Act to authorize the Secretary of Health and Human Services, through the NIH Office of the Director, to carry out a program of research, training, and investigation related to Down syndrome, known as the INCLUDE Project. The bill includes findings on Down syndrome prevalence and co-occurring conditions but does not specify an authorized funding amount. As an authorization bill, it sets policy and spending ceilings but does not allocate actual money; separate appropriations legislation would be required to fund the program. The bipartisan sponsorship (9 cosponsors including Republicans and Democrats) and unanimous consent passage in the Senate indicate broad support, but the lack of a House companion bill and the procedural nature of authorization limit immediate market relevance. No specific companies or sectors beyond healthcare research are directly affected, and the bill does not create procurement or contracting opportunities for publicly traded firms. The legislative path forward requires House passage and presidential signature, but even then, funding depends on future appropriations.

Key Legislators

Sen. Hickenlooper, John W. [D-CO]

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderAug 6, 2026

Continuing to Protect the Meaning and Value of American Citizenship

This executive order directs federal agencies, including State, Justice, Homeland Security, and Social Security, to deny U.S. citizenship documentation to children born in the U.S. whose parents include alien enemies, foreign government employees, or those involved in commercial birth tourism or surrogacy, or who are born in territories without statutory citizenship. It implements a narrow interpretation of the Fourteenth Amendment following the Supreme Court's decision in Trump v. Barbara, effectively restricting birthright citizenship for specific categories of non-citizen parents.

Exec OrderAug 6, 2026

Ending Birth Tourism

This executive order directs the Secretaries of State and Homeland Security to prevent foreign nationals from entering the U.S. on nonimmigrant visas for the purpose of giving birth (birth tourism), including revoking visas, barring entry, and taking action against facilitators. It defines birth tourism as entry via nonimmigrant visa for childbirth and allows humanitarian or national interest exemptions.

proclamationJul 13, 2026

Regulatory Relief for Certain Stationary Sources to Promote American Chemical Manufacturing Security

President Trump issued a proclamation exempting certain chemical manufacturing facilities from compliance with the EPA's HON Rule for two years, citing unavailability of required technology and national security concerns. The exemption delays emissions-control deadlines and maintains pre-HON Rule standards for listed stationary sources, invoking authority under Clean Air Act section 112(i)(4).

Free — no credit card

Get the next market-moving signal before the news does

HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.

Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.

Free forever plan · No credit card · Unsubscribe in one click

Want the live terminal too? Create a free account →